Therefore, these data suggest that the combination of a drug inducing ERα degradation (i.e., LMX) with a drug blocking ERα transcriptional activities and functions (i.e., Tam) in LumA IDC could be an effective approach to treat this kind of breast tumor. Here, ESR1 is linked to breast neoplasm.